Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?
Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 2 therapeutic monoclonal antibodies (MAbs).
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.
Integral Molecular Enables Membrane Protein Antibody Discovery
With a 95% success rate, Integral Molecular is the leader in isolating MAbs against complex membrane proteins, including GPCRs, ion channels, transporters and viral proteins.
With 15+ years experience, Integral Molecular is the industry leader in isolating and characterizing complex membrane proteins.
Integral Molecular’s technologies have contributed to scientific discoveries featured in 60+ peer-reviewed publications.
Your success is crucial to us. We work hard to understand your needs, and strive to exceed your expectations.
Membrane Protein Solutions
MPS Antibody Discovery
Integral Molecular harnesses a full suite of Membrane Protein Solutions to deliver lead MAbs.
Lipoparticles are virus-like particles that concentrate membrane proteins in their native-conformation for better immunization and screening.
Detailed epitope mapping informs antibody mechanism of action and strengthens intellectual property.
Membrane Proteome Array
The Membrane Proteome Array utilizes 5,300 human membrane proteins to profile MAb specificity and evaluate off-target safety.
Integral Molecular offers innovative tools including Reporter Virus Technology for faster characterization of immune responses.
We offer licensing opportunities for therapeutic antibodies against untapped targets.